Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.

Autor: Krueger AC; AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA. a.chris.krueger@abbvie.com, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ
Jazyk: angličtina
Zdroj: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2013 Jun 15; Vol. 23 (12), pp. 3487-90. Date of Electronic Publication: 2013 May 01.
DOI: 10.1016/j.bmcl.2013.04.057
Abstrakt: The synthesis and structure-activity relationships of a novel aryl uracil series which contains a fused 5,6-bicyclic ring unit for HCV NS5B inhibition is described. Several analogs display replicon cell culture potencies in the low nanomolar range along with excellent rat pharmacokinetic values.
(Copyright © 2013. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: